Quality of Life in Schizophrenia

Maurício Silva de Lima, Jair de Jesus Mari, Alan Breier, Anna‐Maria Costa, Eduardo Pondé de Sena, Matthew Hotopf

The Journal of Clinical Psychiatry · 2005 · 42 citations · 0 references

Abstract

Compared with FGAs, olanzapine has advantages in terms of improvements of negative symptoms and quality of life. It is also associated with fewer incidences of tardive dyskinesia and greater increases in weight and BMI. These findings are highlighted by the naturalistic approach adopted in this trial.